Biological markers for therapeutic trials in Alzheimer’s disease
- 11 April 2003
- journal article
- review article
- Published by Elsevier BV in Neurobiology of Aging
- Vol. 24 (4), 521-536
- https://doi.org/10.1016/s0197-4580(03)00002-2
Abstract
No abstract availableKeywords
This publication has 153 references indexed in Scilit:
- Early inflammation and dementia: A 25‐year follow‐up of the Honolulu‐Asia aging studyAnnals of Neurology, 2002
- Three-year follow-up of cerebrospinal fluid tau, β-amyloid 42 and 40 concentrations in Alzheimer's diseaseNeuroscience Letters, 2000
- Increased S100β in the cerebrospinal fluid of patients with frontotemporal dementiaNeuroscience Letters, 1997
- Increased incidence of anti-β-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's diseaseMechanisms of Ageing and Development, 1997
- Increased plasma apolipoprotein E (apoE) levels in Alzheimer's diseaseNeuroscience Letters, 1997
- Human brain S100β and S100β mRNA expression increases with age: Pathogenic implications for Alzheimer's diseaseNeurobiology of Aging, 1996
- Oxidative DNA damage induced by simultaneous generation of nitric oxide and superoxideFEBS Letters, 1995
- VH and VL Gene Usage by Anti-β-Amyloid Autoantibodies in Alzheimer's Disease: Detection of Highly Mutated V Regions in both Heavy and Light ChainsClinical Immunology and Immunopathology, 1995
- Oxidative damage to mitochondrial DNA is increased in Alzheimer's diseaseAnnals of Neurology, 1994
- Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimer's diseaseAnnals of Neurology, 1992